As of Jan 18
| +0.01 / +0.17%|
The 8 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 6.50, with a high estimate of 11.00 and a low estimate of 4.00. The median estimate represents a +7.79% increase from the last price of 6.03.
The current consensus among 9 polled investment analysts is to Hold stock in Keryx Biopharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.